Insider Buying Stocks
LYEL is part of our Insider Buying Stocks list, indicating stock insiders are buying the stock.
LYELL IMMUNOPHARMA INC (LYEL) Stock Price & Overview
NASDAQ:LYEL • US55083R2031
Current stock price
24.78 USD
+0.88 (+3.66%)
At close:
24.78 USD
0 (0%)
After Hours:
The current stock price of LYEL is 24.78 USD. Today LYEL is up by 3.66%. In the past month the price increased by 25.79%. In the past year, price increased by 175.21%.
LYEL Key Statistics
52-Week Range7.65 - 45
Current LYEL stock price positioned within its 52-week range.
1-Month Range18.3001 - 25.25
Current LYEL stock price positioned within its 1-month range.
- Market Cap
- 577.622M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -16.06
- Dividend Yield
- N/A
LYEL Stock Performance
Today
+3.66%
1 Week
+3.94%
1 Month
+25.79%
3 Months
-1.90%
Longer-term
6 Months +40.48%
1 Year +175.21%
2 Years -42.90%
3 Years -38.97%
5 Years N/A
10 Years N/A
LYEL Stock Chart
LYEL Stock Screens
LYEL currently appears in the following ChartMill screener lists.
LYEL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LYEL. When comparing the yearly performance of all stocks, LYEL is one of the better performing stocks in the market, outperforming 94.77% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
LYEL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LYEL. While LYEL seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LYEL Earnings
On March 12, 2026 LYEL reported an EPS of -7.5 and a revenue of 6.00K. The company missed EPS expectations (-229.52% surprise) and missed revenue expectations (-51.78% surprise).
Next Earnings DateMay 11, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported-$7.50
Revenue Reported6K
EPS Surprise -229.52%
Revenue Surprise -51.78%
LYEL Forecast & Estimates
10 analysts have analysed LYEL and the average price target is 40.12 USD. This implies a price increase of 61.9% is expected in the next year compared to the current price of 24.78.
For the next year, analysts expect an EPS growth of 38.36% and a revenue growth -52.49% for LYEL
Analysts
Analysts78
Price Target40.12 (61.9%)
EPS Next Y38.36%
Revenue Next Year-52.49%
LYEL Groups
Sector & Classification
LYEL Financial Highlights
Over the last trailing twelve months LYEL reported a non-GAAP Earnings per Share(EPS) of -16.06. The EPS decreased by -1.65% compared to the year before.
Income Statements
Revenue(TTM)36.00K
Net Income(TTM)-274.45M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.71% | ||
| ROE | -110.57% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-87.5%
Sales Q2Q%-45.45%
EPS 1Y (TTM)-1.65%
Revenue 1Y (TTM)-40.98%
LYEL Ownership
Ownership
Inst Owners46.72%
Shares23.31M
Float15.80M
Ins Owners0.62%
Short Float %7.2%
Short Ratio10.81
LYEL Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LYEL
Company Profile
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 161 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Company Info
IPO: 2021-06-17
LYELL IMMUNOPHARMA INC
201 Haskins Way, Suite 301
South San Francisco CALIFORNIA US
CEO: Elizabeth Homans
Employees: 300
Phone: 13025310855
LYELL IMMUNOPHARMA INC / LYEL FAQ
What does LYELL IMMUNOPHARMA INC do?
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 161 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
What is the current price of LYEL stock?
The current stock price of LYEL is 24.78 USD. The price increased by 3.66% in the last trading session.
What is the dividend status of LYELL IMMUNOPHARMA INC?
LYEL does not pay a dividend.
What is the ChartMill technical and fundamental rating of LYEL stock?
LYEL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for LYELL IMMUNOPHARMA INC?
LYELL IMMUNOPHARMA INC (LYEL) operates in the Health Care sector and the Biotechnology industry.
How many employees does LYELL IMMUNOPHARMA INC have?
LYELL IMMUNOPHARMA INC (LYEL) currently has 300 employees.
What is the Short Interest ratio of LYELL IMMUNOPHARMA INC (LYEL) stock?
The outstanding short interest for LYELL IMMUNOPHARMA INC (LYEL) is 7.2% of its float.